Effects of lysine-vasopressin and 1-deamino-8-D-arginine-vasopressin on memory in healthy individuals and diabetes insipidus patients.
Level 3 - non-randomized controlled study
Non-randomized controlled comparative interventional study
PubMed 7178372 · doi:10.1016/0306-4530(82)90011-7
What was done
Researchers evaluated short- and long-term memory, attention, and concentration in patients with central diabetes insipidus (DI) compared to healthy individuals. Participants received lysine-vasopressin (LVP) or 1-deamino-8-D-arginine-vasopressin (DDAVP) via either a single intramuscular injection or sub-chronic intranasal administration to observe effects on memory function.
What was found
The abstract provides no numerical data, sample sizes, or p-values. It states that central DI patients showed impairments in short- and long-term memory (with intact attention and concentration) relative to healthy controls, and that both acute intramuscular and sub-chronic intranasal administration of LVP or DDAVP normalized memory in DI patients and improved memory in healthy individuals.
Why it matters
The study suggests an association between central vasopressin deficiency and memory impairment, and indicates that vasopressin analogues can influence human memory performance.
Limits
Sample sizes, demographic details, exact dosages, and quantitative statistical metrics are omitted from the abstract. There is no mention of randomization, blinding, or placebo control.
Cited by
- supports Intranasal vasopressin enhances short-term memory performance.